Analyst Conference Summary

biotechnology

Ligand Pharmaceuticals
LGND

conference date: October 29, 2026 @ 5:30 AM Pacific Time
for quarter ending: September 30, 2026 (third quarter, Q3 2026)


I took an initial position 5/7/2026 Forward-looking statements

Overview: Royalty revenue up significantly y/y, but GAAP total revenue down y/y due to a one-time benefit in Q3 2025.

Basic data (GAAP):

Revenue was $78.7 million, up 23% sequentially from $64 million, but down 32% from $115.5 million year-earlier.

Net Income was negative $28.5 million, down sequentially from $48.5 million, and down from $117.3 million year-earlier.

EPS (Earnings per Share), diluted, were negative $1.43, down sequentially from $2.42, and down from $5.68 year-earlier.

Guidance:

Full year 2026: unchanged. Royalty revenue $225 to $250 million; Captisol revenue $35 to $40 million; contract revenue $10 to $20 million. Total $270 to $310 million. But raised non-GAAP, diluted EPS range to $9.50 to $9.75. Q4 may be above Q3 because tier rates increase and first full quarter after XOMA acquisition, plus possible milestone payments.

Conference Highlights:

CEO Todd Davis said, "Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari. We also continued to put capital to work in differentiated assets, acquiring a royalty interest in Santen’s Ryjunea and entering into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline. With a strong balance sheet and a portfolio of over 200 assets, we are well positioned to continue executing our royalty aggregation strategy, and we look forward to sharing an updated five-year outlook at our investor day on December 8th." Ligand reviewed over 180 opportunities in 2026; in Q3 made 2 new investments. Filspari is not wht largest royalty asset. Because of report timing by partners, royalties may be based on estimates that are trued up in the following quarter.

Prediced a 23% CAGR (compound growth rate) for royalty receipts through 2030, but has reason to believe that me be adjusted upward at a later date.

Revenue consisted of $47.4 million for intangible royalty assets; $22.9 million from financial royalty assets; $8 million Captisol; and $0.5 million contract and other. Ligand has a pure royalty aggregation model. In Q3 royalty revenue increased 51% y/y. This was primarily due to royalties on Travere Therapeutics Filspari and Merck Ohtuvayre.

Total core revenue was woen 9% y/y due to a $24.5 million out license fee recorded Q3 2025. Excluding that fee core revenue grew 26% y/y.

In 2027 expects 7 pivotal trial readouts, including Orchestra BioMed's AVIM, Mirum's volixibat, LeonaBio's lasofoxifene, ojemda, Takeda's mezagitamab oseavampator, and Rezolute's Ersodetug.

At the begining of Q3 2026 announced Ligand completed acquisition of XOMA, also a biotech royalty aggregtor, for $39 pershare plus a CVR. The deal had been announced in April. Added 7 commercial and 14 pipeline products to Ligand's portfolio.

"Prior-year results included $53.1 million of income related to Pelthos. Of that, $24.5 million was attributable to the Zelsuvmi out-license and was included in core revenues, and the $28.6 million gain on the sale was excluded. Growth rates that exclude this income compare the periods on a like-for-like basis."

In Q3 2026 Ligand announced would acquire a milestone and royalty interest in Santen Pharmaceutical's Ryjunea from Sydnexis for a $23 million upfront. Ligand acquired a 100% interest in certain payments and related rights under Sydnexis's existing license agreement with Santen. Rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East and Africa, and certain milestone payments.

In Q3 2026 Ligand agreed to finance AvenCell Therapeutics cancer CAR-T therapies for $41 million in exchange for royalties on all future sales of AvenCell pipeline assets. In four tranches. Also taking $6 million in concomitant Series C financing.

In Q4 the FDA accepted Palvella filing and granted Priority Review of the NDA for Qtorin rapamycin for the treatment of microcystic lymphatic malformations. PDUFA target action date is February 28, 2027.

In Q3 Orchestra Biomed announced AVIM therapy received as second Breakthrough Device Designation from the FDA and Virtue SAB trial continued advancement. AVIM therapy achieved full global enrollment in Q4 (October 1, 2026)

In Q3, September, 2026, Ipsen announced the Japan approved Ojemda for low-grade glioma harboring a BRAF mutation or fusion gene.

In Q3 and Q4 Rezolute's ersodetug continued to make progress, with Phase 3 data expected in December 2026.

In Q3 2026, Ovid (with Ligand due for royalties and share of milestones) announced it acquired equity in soticlestat.

Cash and equivalents ended at $447 million, down sequentially from $1.36 billion due to the XOMA acquisition. In Q3 issued convertible senior notes due 2031.

Non-GAAP diluted EPS was $2.67, up sequentially from $2.37, and down from $3.09 year-earlier. Adjusted net income was $57.5 million, up sequentially from $51 million, and down y/y from $63.8 million.

Operating costs of $95 million consisted of: $3 million cost of goods sold, $10 million amortization of intangibles, $3 million R&D, $73 million G&A, $6 million fair value adjustments. Leaving income from operations of negative $16 million. Loss from short-term investments $4 million; loss in equity investments $36 million; interest $2.6 million; other $8.6 million. Income tax benefit $16 million.

Q&A selective summary:

Xoma portfolio incremental value? Given the portfolio size, we triaged. Digging more, we have seen some assets that we wrote to zero that now appear to be shots on goal. We continue to investigate the portfolio carefully.

Still comfortable with $1.50 earnings from Xoma in 2027? No change there, but we have improved our views of the longer term viability of the portfolio. Cost synergies are better than expected.

2027 pace of capital deployment? Rate is accelerating. But below $200 million per year, for now. Pace or selectivity could go up in the future.

Implied Q4 royalty guidance, low end of range? We agree, we are confident we will get to the mid to high end. But we are still waiting for many of our partners to report.

Competition for deals? In addition to internal expertise, we get the best external expertise we can on deals. We are comfortable with our activity level. [no statement re competition]

Q4 potential upside drivers? We have line of site on expenses. Topline depends on order flow, regulatory and clinical milestones.

We are confident in Santen's ability to continue to roll out Ryjunea.

OpenIcon Analyst Conference Summaries Main Page

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALLO
 ALNY
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 BOLD
 BMY
 CBIO
 CCCC
 CDTX
 CLDX
 FATE
 GILD
 GLYC
 ILMN
 INCY
 INKT
 INO
 IONS
 IOVA
 LGND
 MCHP
 MRNA
 NVCR
 REGN
 RXRX
 SANA
 SUPN
 VSTM
 VRTX
 XNCR

       

Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2026 William P. Meyers